# US 11,433,048 B2 · CXCR4 receptor-binding compounds useful for increasing interferon level

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,048 B2
- Document ID: US11433048B2
- Status: Granted
- Kind: B2
- Application number: 16/310,149
- Filed: 2017-06-16
- Published: 2019-06-13
- Granted: 2022-09-06
- Earliest claimed: 2016-06-16
- Applicants: CENTRE NATIONAL de la RECHERCHE SCIENTIFIQUE; Universite Paris Descartes
- Inventors: Nicolas Pietrancosta; Nikaïa Smith; Jean-Philippe Herbeuval
- Web page: https://patentgrep.com/patent/US11433048B2

## CPC

- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/4164: 1,3-Diazoles
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61P 31/18: for HIV
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6866: {Interferon}
- G16B 35/20: Screening of libraries
- G16C 20/64: Screening of libraries
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).

## Claims

### Claim 1

A method for increasing or restoring interferon (IFN) level in an individual in need thereof, the method comprising administering to the individual a CXCR4 receptor-binding compound, wherein the interferon is a type-I interferon (IFN-I), and wherein the CXCR4 receptor-binding compound is plerixafor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the CXCR4 receptor-binding compound interacts with at least 6 amino acids of a CXCR4 receptor represented by SEQ ID NO: 1, wherein the amino acids are selected from the group consisting of alanine 175, aspartic acid 171, aspartic acid 262, phenylalanine 174, valine 196, glycine 207, tyrosine 255, tyrosine 256, isoleucine 259, serine 263 and glutamic acid 288.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the interferon (INF) is IFN-α and/or IFN-β.

### Claim 4 (depends on 1)

The method according to claim 1, for increasing or restoring IFN secretion by immune cells.

### Claim 5 (depends on 1)

The method according to claim 1, for increasing or restoring IFN secretion by immune cells selected from the group consisting of plasmacytoid dendritic cells, monocytes and NK cells.

### Claim 6 (depends on 1)

The method according to claim 1, for preventing or treating a disease selected from the group consisting of a viral infection, an opportunistic infection, allergy, rheumatoid arthritis, multiple sclerosis, a cancer with an overproduction of spermine, depression-induced immunosuppression and diabetes.

### Claim 7 (depends on 1)

A method for increasing or restoring type-I IFN secretion by immune cells comprising the in vitro use of a CXCR4 receptor-binding compound as defined in claim 1.